Match!
Jeffrey N. Weitzel
City of Hope National Medical Center
CancerOncologyBreast cancerGeneticsMedicine
313Publications
51H-index
12.5kCitations
What is this?
Publications 333
Newest
#1Haoyu Zhang (Johns Hopkins University)H-Index: 2
#2Thomas U. Ahearn (NIH: National Institutes of Health)H-Index: 7
Last. Manjeet K. Bolla (University of Cambridge)H-Index: 30
view all 272 authors...
Breast cancer susceptibility variants frequently show heterogeneity in associations by tumor subtype1–3. To identify novel loci, we performed a genome-wide association study including 133,384 breast cancer cases and 113,789 controls, plus 18,908 BRCA1 mutation carriers (9,414 with breast cancer) of European ancestry, using both standard and novel methodologies that account for underlying tumor heterogeneity by estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 ...
Source
#1Sonia S. Kupfer (U of C: University of Chicago)H-Index: 20
#2Samir Gupta (UCSD: University of California, San Diego)H-Index: 17
Last. Jewel Samadder (Mayo Clinic)
view all 4 authors...
Source
#1Mary B. Daly (Fox Chase Cancer Center)H-Index: 77
#2Robert Pilarski (OSU: Ohio State University)H-Index: 37
Last. John J. Garber (Brigham and Women's Hospital)H-Index: 130
view all 33 authors...
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel...
3 CitationsSource
#1Phuong L. Mai (University of Pittsburgh)H-Index: 3
#2Sharon Sand (City of Hope National Medical Center)H-Index: 14
Last. Karina Miranda SantiagoH-Index: 3
view all 26 authors...
Background: The success of multi-site collaborative research relies on effective data collection, harmonization and aggregation strategies. Data Coordination Centers (DCCs) serve to facilitate the implementation of these strategies. The utility of a DCC can be particularly relevant for research on rare diseases where collaboration from multiple sites to amass large aggregate data sets is essential. However, approaches to building a DCC have been scarcely documented. Methods and Materials: The Li...
Source
#1Thomas P. Slavin (City of Hope National Medical Center)H-Index: 10
#2Can-Lan Sun (City of Hope National Medical Center)H-Index: 18
Last. Jeffrey N. Weitzel (City of Hope National Medical Center)H-Index: 51
view all 10 authors...
Abstract Objective Our goal was to identify pathogenic variants (PV) associated with germline cancer predisposition in an unselected cohort of older breast cancer survivors. Older patients with cancer may also be at higher risk for clonal hematopoiesis (CH) due to their age and chemotherapy exposure. Therefore, we also explored the prevalence of PVs suggestive of CH. Methods We evaluated 44 older adults (65 years or older) diagnosed with breast cancer who survived at least two years after diagno...
Source
#1Andrea Campos-Carrillo (City of Hope National Medical Center)
#2Jeffrey N. Weitzel (City of Hope National Medical Center)H-Index: 51
Last. Thomas P. Slavin (City of Hope National Medical Center)H-Index: 10
view all 11 authors...
Abstract Circulating tumor DNA holds substantial promise as an early detection biomarker, particularly for cancers that do not have currently accepted screening methodologies, such as ovarian, pancreatic, and gastric cancers. Many features intrinsic to ctDNA analysis may be leveraged to enhance its use as an early cancer detection biomarker: including ctDNA fragment lengths, DNA copy number variations, and associated patient phenotypic information. Furthermore, ctDNA testing may be synergistical...
Source
#1Helian Feng (Harvard University)H-Index: 3
Last. Antonis C. AntoniouH-Index: 60
view all 252 authors...
Previous transcriptome-wide association studies (TWAS) have identified breast cancer risk genes by integrating data from expression quantitative loci and genome-wide association studies (GWAS), but analyses of breast cancer subtype-specific associations have been limited. In this study, we conducted a TWAS using gene expression data from GTEx and summary statistics from the hitherto largest GWAS meta-analysis conducted for breast cancer overall, and by estrogen receptor subtypes (ER+ and ER-). W...
Source
#1Xin Yang (University of Cambridge)H-Index: 2
#2Goska Leslie (University of Cambridge)H-Index: 5
Last. Marc Tischkowitz (University of Cambridge)H-Index: 39
view all 119 authors...
PURPOSETo estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germl...
7 CitationsSource
#1Chi Gao (Harvard University)H-Index: 2
#2Eric C. Polley (Mayo Clinic)H-Index: 21
Last. Paul Auer (Emory University)
view all 23 authors...
Background: Pathogenic variants detected in multi-gene cancer predisposition panels are increasingly used to counsel women regarding their risk for breast cancer. However, the clinical implications of moderate penetrance genes (e.g. CHEK2, ATM) remain unclear. Breast MRI is indicated for women with a lifetime risk of breast cancer of >20%, and polygenic risk scores (PRS) based on common variants discovered in recent genome-wide association studies (GWAS) may identify women with pathogenic varian...
Source
#1Susan L. Neuhausen (City of Hope National Medical Center)H-Index: 63
#2Daniel Schmolze (City of Hope National Medical Center)H-Index: 3
Last. Kevin Gardner (Columbia University)H-Index: 1
view all 14 authors...
Background: Latinos represent the largest and fastest-growing minority population in the US; breast cancer is the most common cancer and causes the most cancer deaths in this population. Precision medicine is being applied increasingly to guide breast cancer treatment decisions. However, the ability to apply precision medicine for prognosis and targeted treatments for breast cancer in Latinas is limited by insufficient data on somatic mutation and gene expression profiles in available tumor muta...
Source
12345678910